bioAffinity Technologies (BIAF) Assets Average (2022 - 2026)

bioAffinity Technologies (BIAF) has reported Assets Average for 5 consecutive years, with $9.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 56.75% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $9.5 million (up 56.75% YoY), while the FY2025 annual figure was $8.7 million, up 18.59% from the prior year.
• Assets Average declined to $9.5 million in Q1 2026 per BIAF's latest filing, from $11.3 million in the prior quarter.
• Across five years, Assets Average topped out at $13.1 million in Q4 2022 and bottomed at $5.1 million in Q2 2025.
• Historically, Assets Average has averaged $8.7 million across 5 years, with a median of $8.7 million in 2023.
• Annual changes were most pronounced in 2024 — Assets Average tumbled 30.71% — and 2025, when it jumped 72.26%.
• bioAffinity Technologies' Assets Average stood at $13.1 million in 2022, then declined by 29.85% to $9.2 million in 2023, then dropped by 29.03% to $6.5 million in 2024, then jumped by 72.26% to $11.3 million in 2025, then declined by 16.0% to $9.5 million in 2026.
• Business Quant data shows BIAF's Assets Average at $9.5 million in Q1 2026, $11.3 million in Q4 2025, and $8.1 million in Q3 2025.